Last reviewed · How we verify
Omacetaxine Mepesuccinate Injection — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Omacetaxine Mepesuccinate Injection (Omacetaxine Mepesuccinate Injection) — The University of Hong Kong.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Omacetaxine Mepesuccinate Injection TARGET | Omacetaxine Mepesuccinate Injection | The University of Hong Kong | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Omacetaxine Mepesuccinate Injection CI watch — RSS
- Omacetaxine Mepesuccinate Injection CI watch — Atom
- Omacetaxine Mepesuccinate Injection CI watch — JSON
- Omacetaxine Mepesuccinate Injection alone — RSS
Cite this brief
Drug Landscape (2026). Omacetaxine Mepesuccinate Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/omacetaxine-mepesuccinate-injection. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab